c6 peptide elisa B. burgdorferi (Lyme) ELISA kit - c3-peptide-for-sale performance evaluation of the C6 Lyme ELISA kit The C6 Peptide ELISA: A Key Tool in Lyme Disease Diagnosis

ca-peptide The C6 peptide ELISA has emerged as a significant diagnostic tool in the serological detection of Lyme disease, offering enhanced accuracy and efficiency. This enzyme-linked immunosorbent assay (ELISA) leverages a specific peptide derived from a crucial protein of the Lyme disease-causing bacteria, *Borrelia burgdorferi*. Understanding the intricacies of this test, its components, and its applications is vital for healthcare professionals and researchers alike.

At its core, the C6 peptide is a synthetic peptide representing a conserved region (IR6) of the VlsE (Vmp-like sequence expressed) surface protein of *Borrelia* speciesC6 peptide ELISA test in the serodiagnosis of Lyme .... The VlsE protein is known to be immunogenic, meaning it elicits a strong immune response in infected individuals. This makes the C6 peptide an excellent target for antibody detection. The C6 peptide ELISA works by detecting the presence of both IgG and IgM antibodies against the C6 peptide in a patient's serum. These antibodies are produced by the immune system in response to infection with *Borrelia* bacteria.

The diagnostic utility of the C6 peptide ELISA has been extensively studied and validated作者：D Nyman·2006·被引用次数：27—Assay ofC6antibodies clearly improved the diagnostic performance for the group with definite LB. The combination ofC6and IgGELISAtests was marginally .... Research has demonstrated that this assay can be used to diagnose Lyme disease, with studies highlighting its potential as a first-line test. For instance, the synthetic C6 peptide test has been evaluated as part of a two-tiered diagnostic scheme for Borrelia serology. The results have often shown that the C6 ELISA was significantly more sensitive than 2-tier testing, particularly in early Lyme disease.作者：AR Marques·2002·被引用次数：49—The C6 peptide ELISAcan be used to diagnose Lyme diseasein patients who have received the OspA vaccine. This increased sensitivity means the test can detect the infection earlier, allowing for prompt treatment. A positive C6 test seems to correlate well with acute borreliosis, making it a valuable indicator of active infectionSensitivity of Bb C6 peptide based PHOSPHAN and ....

A notable advantage of the C6 peptide ELISA is its ability to differentiate between antibodies generated by natural infection and those from vaccination.C6 peptide test may indicate Borrelia miyamotoi infection Antibodies to the C6 peptide are an indication of natural infection, as antibodies generated as a result of Lyme vaccination do not typically react with this specific peptide. This is crucial because it allows for an accurate diagnosis even in patients who have received the OspA vaccine, where conventional tests might yield false positives.Single-tier testing with the C6 peptide ELISA kit compared ... Therefore, the C6 peptide ELISA can be used to diagnose Lyme disease in patients who have received the OspA vaccineBorrelia Vmp-like sequence expressed (VlsE) C6 peptide-Biotin (>90%) for ELISA. Availability, In Stock. Product Type, Antibody Blocking Peptide..

The performance evaluation of the C6 Lyme ELISA kit has been a subject of numerous multicenter studies. These evaluations have consistently affirmed the test's reliability. The B.Human C6 ELISA Kit burgdorferi (Lyme) ELISA kit based on the C6 peptide of the VlsE protein offers a significant advancement in diagnostic accuracy. The C6 peptide sequence is highly antigenically reactive, meaning it reliably triggers an immune response that can be detected by the ELISA.VlsE C6 peptide and IgG ELISA antibody analysis... This high reactivity contributes to the test's ability to detect antibodies shortly after infectionC6 peptide ELISA test in the serodiagnosis of Lyme ....

Furthermore, the C6 peptide ELISA has shown high sensitivity and specificity not only in serum but also on cerebrospinal fluid samples, proving valuable in the diagnosis of Lyme neuroborreliosis. The detection of IgM and IgG antibodies of C6 peptides using ELISA has a sensitivity of over 70% for detecting Lyme disease. While some studies have compared single-tier testing with the C6 peptide ELISA kit against traditional two-tier testing, the findings generally support the C6 ELISA as a standalone or primary diagnostic tool, offering increased sensitivity in early Lyme disease with comparable sensitivity in later stages. The assay's ability to detect both IgG and IgM antibodies against the C6 peptide provides a comprehensive picture of the immune response.

Beyond Lyme disease, emerging research suggests the C6 peptide test may also be helpful in identifying other tick-borne infections, such as *Borrelia miyamotoi*The C6 peptide ELISAcan be used to diagnose Lyme disease in patients who have received the OspA vaccine. Formats available. You can view the full content in .... This broadens the potential applications of this versatile diagnostic method.

It is important to distinguish between the C6 peptide ELISA for Lyme disease and a Human Complement C6 ELISA Kit or a Human C6 (Complement C6) ELISA Kit. While both utilize the ELISA technique, the former targets antibodies related to *Borrelia* infection, whereas the latter quantifies human complement protein C6 in biological samples.Human Complement C6 ELISA Kit (ab125965) The mechanism of the Human C6 ELISA Kit is often based on C6 antibody-C6 antigen interactions (immunosorbency) and an HRP colorimetric detection system.

In summary, the C6 peptide ELISA is a sophisticated and highly effective diagnostic assay.作者：AR Marques·2002·被引用次数：49—The C6 peptide ELISAcan be used to diagnose Lyme diseasein patients who have received the OspA vaccine. Its specificity for antibodies generated by natural infection, coupled with its high sensitivity, particularly in early disease stages, makes it an indispensable tool in the fight against Lyme diseaseHuman C6 ELISA Kit. The ongoing research and validation studies continue to solidify its role in accurate and timely diagnosis, contributing to better patient outcomes. The availability of kits like the VlsE C6 peptide-Biotin (>90%) for ELISA further supports the development and execution of these crucial diagnostic tests.